Viridian Therapeutics, Inc.
VRDN
$13.13
$0.483.79%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -3.82% | -12.97% | -80.41% | -82.59% | -82.28% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -3.82% | -12.97% | -80.41% | -82.59% | -82.28% |
| Cost of Revenue | 32.79% | 119.30% | 77.59% | 52.97% | 112.71% |
| Gross Profit | -32.85% | -119.79% | -79.61% | -54.67% | -116.19% |
| SG&A Expenses | -35.70% | 9.23% | 42.11% | 81.27% | 170.02% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.50% | 21.93% | 18.39% | 30.47% | 87.22% |
| Operating Income | -17.52% | -21.98% | -19.08% | -31.50% | -89.46% |
| Income Before Tax | -13.55% | -18.66% | -15.24% | -26.57% | -83.05% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -13.55% | -18.66% | -15.24% | -26.57% | -83.05% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.55% | -18.66% | -15.24% | -26.57% | -83.05% |
| EBIT | -17.52% | -21.98% | -19.08% | -31.50% | -89.46% |
| EBITDA | -17.55% | -21.98% | -19.03% | -31.43% | -89.43% |
| EPS Basic | 21.31% | 40.28% | 38.69% | 30.44% | -0.74% |
| Normalized Basic EPS | 25.57% | 15.49% | 12.78% | 3.36% | -32.04% |
| EPS Diluted | 21.31% | 40.28% | 38.69% | 30.44% | -0.74% |
| Normalized Diluted EPS | 25.57% | 15.49% | 12.78% | 3.36% | -32.04% |
| Average Basic Shares Outstanding | 51.78% | 42.05% | 36.62% | 37.01% | 39.53% |
| Average Diluted Shares Outstanding | 51.78% | 42.05% | 36.62% | 37.01% | 39.53% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |